Skip to Content

MRD analysis in 1L Treatment of CLL in Elderly or Unfit patients

In this MEDtalk Tahla Munir, Department of Haematology, St James’s University Hospital, Leeds, United Kingdom, presents the results of the Glow Study. In this study Ibrutinib plus venetoclax demonstrated superior uMRD responses that were deeper and better sustained post-treatment vs chlorambucil plus Obinutuzumab in elderly or unfit patients with previously untreated CLL.

Talha Munir

Lue artikkeli

Jos olet lääkäri, farmaseutti tai rajatun lääkkeenmääräämisoikeuden omaava sairaanhoitaja, pääset lukemaan artikkelin kirjautumalla käyttäjäksi BestPractice Nordic -sivustolle.

Back to top